glp-1 medicaid More states consider dropping weight loss drugs from • Stateline Medicaid Coverage of and Spending

Z., Chachra, S

Gut-restricted peptide pharmacology Examined as a model of a locally-acting, minimally-absorbed oral peptide

Still, the choice between these classes depends on individual patient needs

Your goals shape everything that follows

Mann JF, Orsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al

Other Popular Peptides in the Gray Zone: Thymosin Alpha-1 Immune support (approved in 35+ countries, NOT in US) GHK-Cu (Copper Peptide) Skin/hair (injectable form banned by FDA) Epitalon Claimed anti-aging (no human studies) LL-37 Antimicrobial (research only) AOD-9604 Fat loss (FDA banned) Semorelin Growth hormone release Melanotan II Tanning (serious side effects) The FDA Crackdown: What Happened in Late 2023 Timeline of the Ban: 2023: FDA adds 12+ peptides to "Category 2 Bulk Drug Substances" list What this means: Compounding pharmacies CANNOT legally make these peptides FDA cites "significant safety risks" No approved use in humans Peptides specifically banned from compounding: BPC-157 TB-500 (Thymosin Beta-4 fragment) Thymosin Alpha-1 CJC-1295 Ipamorelin AOD-9604 GHK-Cu (injectable) Epitalon LL-37 DSIP KPV Selank Semax And more